Shared Risk Agreements Health Care

Zaric GS, O`Brien BJ. Analysis of a pharmaceutical risk-sharing agreement based on the buyer`s total budget. Health Econ. 2005;14:793–803. With a wider use of risk-sharing contracts, the new paradigm of personalized medicine has developed over the past decade to tailor treatments to patients` characteristics using genetic biomarkers. Patient stratification reduces uncertainties about the clinical and financial outcomes of drugs. Therefore, one might think that risk-sharing arrangements are not appropriate, if not necessary, in this new context; However, this type of agreement can be used to incentivize companies to generate more information about patient characteristics in order to improve clinical outcomes. From a theoretical point of view, Antonanzas et al. [12] analyzed the use of risk-sharing contracts to promote personalized medicine. However, from an empirical point of view, the link between such agreements and the implementation of personalized medicine requires more research, as this issue has not yet been addressed in the literature. Maskineh C, Nasser SC. Managed start-up agreements for pharmaceuticals in the Middle East and North African countries: experience and prospects of payers and manufacturers. Problems recording the integrity of the value.

2018;16:33-8. Walker S, Sculpher M, Claxton K, Palmer S. Coverage with evidence, only in research, risk sharing or patient access patterns? A framework for hedging decisions. Value of health. 2012;15(3):570–9. In some cases, these care management fees may be subject to the minimum quality thresholds mentioned above, but in many cases only shared economies are affected. These costs may also be guaranteed or subject to savings by a service provider organisation, depending on the specific agreement. . . .